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The prevalence of delirium in acute medical inpatients is high, 
with estimates ranging from 10% to 31%.[1] Short- and long-term 
complications of delirium include increased mortality and length of 
hospitalisation, post-discharge institutionalisation, and long-term 
functional and cognitive decline.[2] This is a considerable healthcare 
burden: in developed countries the cost of delirium is equal to 
that of falls and diabetes mellitus.[3] A number of risk factors for 
delirium have been identified, including predisposing factors such 
as dementia and advancing age and acute precipitating factors 
such as drugs, infections and metabolic abnormalities.[2] Protective 
factors include a higher level of education, a marker of cognitive 
reserve.[4] Unfortunately, the data on delirium outcomes and risk 
factors in general medical inpatients are derived almost exclusively 
from geriatric populations in developed countries, a very different 
population to acute medical admissions in developing country 
settings with a high HIV/tuberculosis (TB) burden.[5] Furthermore, 
the few studies from developing country settings such as sub-Saharan 
Africa (SSA) have either been conducted in medical patients aged 
>60 years or in specialised populations, such as psychiatric and 
intensive care settings.[6-8] In developed countries such as the USA, 
studies were done among HIV-infected populations before universal 
access to combination antiretroviral therapy (ART).[9-14]
HIV targets the central nervous system (CNS) with resultant 
neurocognitive impairment (NCI), a well-described predisposing 
risk factor for delirium. Acute and opportunistic infections (OIs), 
also known risk factors for delirium, occur more commonly with 
advancing immunosuppression. It is therefore unsurprising that 
studies have shown high prevalence rates of delirium (3.7 - 57%) 
in HIV-infected populations.[6,11-13] Delirium in HIV is often 
concomitant with NCI, in 8 - 22% of cases.[15] Combination ART both 
prevents and improves NCI and decreases the incidences of acute 
and OIs. Widespread access to ART may therefore mitigate delirium 
risk. It is unclear whether HIV infection remains an independent 
risk factor for delirium in acute medical admissions in endemic 
HIV settings with universal ART programmes.[9] Furthermore, in 
developing country settings such as South Africa (SA), with high 
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Background. Delirium is associated with increased mortality and length of hospital stay. Limited data are available from HIV-infected 
acute hospital admissions in developing countries. We conducted a prospective study of delirium among acute medical admissions in 
South Africa (SA), a developing country with universal antiretroviral therapy (ART) access and high burdens of tuberculosis (TB) and 
non-communicable disease.
Objectives. To identify the prevalence of, risk factors for and outcomes of delirium in HIV-infected individuals in acute general medical 
admissions.
Methods. Three cohorts of adult acute medical admissions to Groote Schuur and Victoria Wynberg hospitals, Cape Town, SA, were 
evaluated for prevalent delirium within 24 hours of admission. Reference delirium testing was performed by either consultant physicians or 
neuropsychologists, using the Confusion Assessment Method.
Results. The study included 1 182 acute medical admissions, with 318 (26.9%) HIV-infected. The median (interquartile range) age and 
CD4 count were 35 (30 - 43) years and 132 (61 - 256) cells/µL, respectively, with 140/318 (44.0%) using ART on admission. The prevalence 
of delirium was 17.6% (95% confidence interval (CI) 13.7 - 22.1) among HIV-infected patients, and delirium was associated with increased 
inpatient mortality. In multivariable logistic regression analysis, factors associated with delirium were age ≥55 years (adjusted odds ratio 
(aOR) 6.95 (95% CI 2.03 - 23.67); p=0.002), and urea ≥15 mmol/L (aOR 4.83 (95% CI 1.7 - 13.44); p=0.003), while ART use reduced risk 
(p=0.014). A low CD4 count, an unsuppressed viral load and active TB were not predictors of delirium; nor were other previously reported 
risk factors such as non-opportunistic acute infections or polypharmacy.
Conclusions. Delirium is common and is associated with increased mortality in HIV-infected acute medical admissions in endemic 
settings, despite increased ART use. Older HIV-infected patients with renal dysfunction are at increased risk for inpatient delirium, while 
those using ART on admission have a reduced risk.
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burdens of communicable diseases (CDs) and non-communicable 
diseases (NCDs), clinicians do not know which delirium risk 
factors to identify among HIV-infected admissions. Available data 
almost exclusively predate universal ART access.[9-13,16] Furthermore, 
data from SSA populations are highly variable, owing to a lack of 
standardised delirium testing methods or incomplete HIV testing.[6]
Objectives
We therefore conducted a study among acute medical admissions with 
a high HIV burden, using standardised delirium diagnostic testing 
methods, in a country with universal access to ART. The objectives 
were to identify the prevalence of, risk factors for and outcomes of 
delirium in HIV-infected individuals admitted to SA hospitals.
Methods
Study design and participants
This prospective cohort study focused on HIV-infected acute general 
medical admissions. The study was a secondary analysis within 
a parent prospective randomised cohort study designed for the 
development and validation of a novel four-question delirium 
screening tool. Prevalent delirium at admission was assessed using 
the Confusion Assessment Method (CAM) as the primary reference 
test to identify patients with delirium. A computer-generated random 
selection of daily acute general medical admissions to two hospitals 
(Groote Schuur Hospital (GSH) and Victoria Wynberg Hospital 
(VWH)) in Cape Town, SA, were enrolled for the parent study during 
two phases: 22 August 2009 - 10 December 2009 (development) and 
11 November 2013 - 7 March 2014 (validation). GSH is a tertiary 
referral hospital with ~150 acute general medical admission beds, 
while VWH is a district-level hospital with ~80 acute general 
medical beds. All adult medical patients aged ≥18 years admitted 
on weekdays were eligible, and a random sample of 10 patients per 
day was selected (usual daily patient intake 15 - 25 patients) to allow 
study staff to perform delirium testing within 24 hours of admission. 
Exclusion criteria were: (i) informed consent declined; (ii) age <18 
years; (iii) Glasgow Coma Scale score ≤12; and (iv) aphasia (Fig. 1).
The primary studies were approved by the University of Cape 
Town-Groote Schuur Hospital Human Research Ethics Committee 
(ref. no. 311/2017). If a patient was diagnosed with delirium during 
reference testing, their initial consent was not considered valid and the 
HREC granted an initial waiver of the informed consent requirement. 
When the patient’s delirium had resolved, the study was explained to 
the patient again and written informed consent was obtained. If this 
was not possible as part of the initial inpatient admission, the patient 
and/or next of kin were contacted and arrangements were made to 
complete consent either in person or telephonically. If the patient was 
uncontactable, the HREC granted a waiver to allow the inclusion of 
patient data. There was no patient involvement.
All data relevant to the study are included in the article or have 
been uploaded as supplementary information (Appendices 1 - 5, 
available at http://samj.org.za/public/sup/15628.pdf).
Delirium testing
Within 24 hours of admission, a study physician reviewed the 
patient’s charts and obtained data pertaining to the primary diagnosis, 
clinical background, admission medication, level of education 
Acute general admissions to two hospitals 
during two phases of enrolment:
August - December 2009 (development) and 
November 2021 - March 2013 (validation)
Patients randomised to study, N=1 565
Development GSH, n=459
Validation GSH, n=609; VWH, n=497
Excluded, n=383
• Informed consent declined, n=45
• Repeat admission, n=73
• Age <18 years, n=12
• GCS ≤12, n=61
• Aphasia, n=62
• Not admitted to a general ward (i.e. admitted to the ICU), n=35
• Died before testing, n=11
• Refused an HIV test, n=25
• No CAM testing, n=35
• CRF missing, n=17 
• Other,* n=7
Patients included in nal analysis, n=1 182
Development GSH, n=395











Fig. 1. Consort diagram. (GSH = Groote Schuur Hospital; VWH = Victoria Wynberg Hospital; GCS = Glasgow Coma Scale score; ICU = intensive care unit; 
CAM = Confusion Assessment Method; CRF = case report form; *Language barrier, deaf, elective admission.)
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and demographic characteristics. A second independent study 
physician trained in delirium testing (in the development study) or a 
neuropsychologist (in the validation study) then assessed the patient 
for delirium using the CAM, performed during a 20 - 30-minute 
interview consisting of formal cognitive testing.[17] For either testing 
tool the presence of language barriers was noted (see Fig. 1), or a 
ward-based translator was used when possible so that testing was 
performed in the patient’s first language. Because delirium has, by its 
very nature, a fluctuating course of symptoms, patients were screened 
twice in 24 hours. However, there is still a possibility that some cases 
of delirium were missed owing to episodes of lucidity.
HIV status, diagnostic, medication and outcome data 
acquisition and classification
Investigations, including HIV screening and testing, were performed 
at the discretion of the attending physicians, and any patients who 
refused HIV testing during this admission were excluded from the 
study. Positive HIV status was defined as any record of a positive 
HIV test (either a rapid test or enzyme-linked immunosorbent assay) 
at any point prior to or during an index admission dating back to 
January 2005 (the earliest available information on the National 
Health Laboratory Service electronic system). The CD4 count and 
HIV viral load (VL) closest to or during the index admission, to a 
maximum of 12 months preceding admission, was included.
The patients’ primary diagnoses and medications were collected by 
reviewing admission case records, pharmacy records and discharge 
summaries and assigning International Statistical Classification 
of Diseases and Related Health Problems, 10th revision (ICD-10) 
diagnosis codes. We analysed the association of delirium with 
the top five most frequent CDs and NCDs, considering known 
HIV-associated conditions separately. Categories of medications 
commonly linked to delirium were selected based on published 
literature,[18] and all medications were assigned to groups as per the 
South African Medicines Formulary. Antiretrovirals (ARVs), anti-TB 
medication, and medication for prophylaxis of OIs (fluconazole and 
trimethoprim/sulfamethoxazole) were assessed as possible protective 
factors for delirium in HIV-infected patients. Detailed information 
on ICD-10 and medication groupings is provided in Appendices 1 
and 2 (http://samj.org.za/public/sup/15628.pdf). Outcome mortality 
data were obtained from patient folders, the hospital electronic 
patient management system and the Western Cape Provincial death 
registry, which links a unique patient identification number with 
national death certificate records and system-wide electronic records.
Statistical analysis
Data were analysed in Stata 14.2 (StataCorp, USA). Categorical 
variables were summarised as frequencies and percentages. 
Sociodemographic and clinical characteristics and outcomes were 
assessed for differences between HIV-infected, HIV-uninfected, 
and HIV unknown patients overall and in those with delirium. The 
analysis was then restricted to HIV-infected patients (n=318) to 
compare sociodemographics, clinical characteristics and outcomes 
between cases with and without delirium. Associations between 
categorical variables were analysed using the χ2 test and Fisher’s exact 
test, as appropriate. The Wilcoxon rank-sum test or the Kruskal-
Wallis test were used to compare continuous variables between two 
and three groups, respectively.
Univariable and multivariable logistic regression analyses were 
performed to identify risk factors for delirium in HIV-infected 
patients. Variables analysed in univariable analysis were considered 
a priori, and receiver operating characteristic (ROC) curve analysis 
was used for age and urea to determine clinically relevant cut-off 
values. Variables were retained in the multivariable model if they 
were significantly associated with outcome (p<0.05) and did not 
have sparse data (renal failure) or were not strongly collinear (urea 
and creatinine, total medication and ARVs). Education ≥7 years and 
CD4 count were retained in the multivariable model regardless of 
significance owing to their clinical relevance. Odds ratios (ORs) were 
reported with 95% confidence intervals (CIs). A p-value <0.05 was 
regarded as statistically significant.
Results
A total of 1 565 patients were randomised to the parent study (459 
and 1 106 in the development and validation phases, respectively) 
(Fig. 1). Of these, 383 were excluded and a total of 1 182 patients 
were considered as part of this analysis. The prevalence of HIV 
infection was 26.9% (n=318/1 182), with 44% (n=140/318) using 
ART on admission. Table 1 and Appendix 5 (http://samj.org.za/
public/sup/15628.pdf) describe the cohort stratified by HIV status 
and then restricted to only patients with delirium. Overall, the 
median (interquartile range (IQR)) age was 49.5 (34 - 63.2) years, 
and 53.1% were female (Table 1). HIV-infected patients were younger 
than the HIV-uninfected and unknown groups (median (IQR) 35 
(0 - 43) years v. 52.7 (38 - 64.7) years and 66 (55.5 - 75.3) years, 
respectively; p=0.0001). The median (IQR) CD4 count was 132 
(61 - 256) cells/µL. The prevalence of delirium was 17.6% in HIV-
infected patients compared with 13.8% in HIV-uninfected patients 
and 11.9% in patients with unknown HIV status (p=0.161). Overall 
inpatient and 12-month mortality was 6.2% (n=72/1 182) and 
23.8% (n=281/1 182), respectively, with no difference by HIV status 
(Table 1). There was no loss to follow-up in either the inpatient or the 
12-month mortality groups. Among HIV-positive patients (Table 2), 
delirium was associated with higher inpatient mortality (14.6% v. 
5.4%; p=0.036), but although HIV-infected patients had a higher 
12-month mortality, the result was not significantly different (33.9% 
v. 22.9%; p=0.083).
Table 1 and Appendix 5 (http://samj.org.za/public/sup/15628.
pdf) show primary admission diagnoses, key laboratory parameters 
and the five most common admission medication categories. NCDs 
accounted for more hospital admissions than CDs (69.7% v. 27.8%; 
p<0.0001), and two distinct patient groups were evident. HIV-
infected patients had low rates of NCDs and a high burden of 
TB and other CDs, such as meningitis/encephalitis. They also 
used more medication (15.1% on three or more medications) 
owing to the prescription of ARVs and greater use of anti-TB 
medication and antibiotics. In contrast, the older HIV-unknown 
group were predominantly admitted with NCDs, and non-steroidal 
anti-inflammatory and cardiac drug prescribing was higher than in 
HIV-positive patients (p<0.0001). These differences were present 
when comparing the overall patient population (Table 1) and when 
restricted to patients with delirium (Appendix 5, http://samj.org.
za/public/sup/15628.pdf). These findings show that HIV-infected 
patients have a unique profile relative to HIV-uninfected general 
medical admissions.
HIV-infected patients are compared in Table 2 according to the 
presence or absence of delirium. The two groups were similar in 
terms of age, gender and education status. With the exception of renal 
failure, there were no significant differences in CD or NCD primary 
diagnoses. Similarly, although patients with delirium had lower 
median CD4 cell counts (104 cells/µL (95% CI 32 - 214) v. 150 cells/µL 
(95% CI 62 - 266); p=0.1284) and lower rates of HIV viral suppression 
(27.3% v. 40%; p=0.519), these differences were not statistically 
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significant. However, the delirium group had significantly lower 
haemoglobin (p=0.0194) and higher urea (p=0.0047) and creatinine 
levels (p=0.0197). A higher number of patients without delirium 
were using three or more admission medications (n=45; 17.2% v. 
n=3; 5.4%; p=0.023), with a greater number of patients on ARVs, 
antibiotics, and OI prophylaxis (trimethoprim/sulfamethoxazole and 
fluconazole). However, use of TB medication in the two groups was 
similar (19.6% v. 19.5%; p=0.976).
Table 3 shows the univariable and multivariable logistic regression 
analysis used to analyse associations with prevalent delirium in 
HIV-infected acute medical admissions. For every 5-year increase in 
age there was a 12% increased risk of delirium (95% CI 0.99 - 1.30; 
p=0.065), with an adjusted odds ratio (aOR) of 6.95 (2.03 - 23.67) using 
an ROC-selected age ≥55 years (p=0.002). On univariable analysis, 
both a primary diagnosis of renal failure (OR 6.3 (95% CI 1.6 - 24.4); 
p=0.007) and ROC-selected urea ≥15 mmol/L increased the risk of 
delirium, with only urea >15 mmol/L retained in the multivariable 
analysis (aOR 4.83 (95% CI 1.7 - 13.44); p=0.0003). Patients using 
three or more medications on admission had a decreased risk of 
delirium (OR 0.3 (95% CI 0.1 - 0.9); p=0.035), with the greatest 
protective effect from the use of ART on admission (aOR 0.34 (95% 
CI 0.14 - 0.8); p=0.014). Other NCDs and CDs, including TB, or 
markers of advanced immunosuppression and poor HIV control 
(CD4 cell count and VL suppression), were not significant risk factors 
for delirium.
Discussion
Our study is the first to study delirium, using a validated testing 
method, among HIV-infected inpatients admitted in the context of an 
acute general medical intake in a developing country with dual CD 






HIV not tested 
(N=160) p-value
Age (years), median (IQR) 49.5 (34 - 63.2) 35 (30 - 43) 52.7 (38 - 64.7) 66 (55.5 - 75.3) 0.0001
Female, n (%) 627 (53.1) 197 (61.9) 335 (47.6) 95 (59.4) <0.0001
Education ≥7 years, n (%) 830 (75.9) 230 (72.3) 488 (74.9) 112 (74.2) 0.332
Delirium present, n (%) 172 (14.6) 56 (17.6) 97 (13.8) 19 (11.9) 0.161
Dementia/cognitive deficit, n (%) 52 (4.4) 8 (2.5) 24 (3.4) 20 (12.5) <0.0001
Primary diagnosis,* n (%) (N=1 153)
NCDs total 824 (69.7) 141 (44.3) 544 (77.3) 139 (86.9) <0.0001
4 most common NCDs
CVS combined 238 (20.1) 29 (9.1) 149 (21.2) 60 (37.5) <0.0001
Respiratory 94 (8.0) 11 (3.5) 72 (10.2) 11 (6.9) 0.001
Cerebrovascular 70 (5.9) 4 (1.3) 49 (7.0) 17 (10.6) <0.0001
Renal failure 42 (3.6) 9 (2.8) 30 (4.3) 3 (1.9) 0.293
CDs total 329 (27.8) 142 (44.7) 165 (23.44) 22 (13.8) <0.0001
4 most common CDs
TB, total 145 (12.3) 92 (28.9) 51 (7.2) 2 (1.3) <0.0001
Pulmonary TB 75 (6.4) 35 (11) 39 (5.5) 1 (0.6) <0.0001
TB meningitis 20 (1.7) 15 (4.7) 5 (0.7) 0 <0.0001
Disseminated TB 33 (2.8) 28 (8.8) 5 (0.7) 0 <0.0001
Pneumonia 88 (7.5) 27 (8.5) 52 (7.4) 9 (5.6) 0.528
Meningitis/encephalitis 21 (1.8) 11 (3.5) 9 (1.3) 0 0.040
UTI 20 (1.7) 0 16 (2.3) 4 (2.5) 0.005
Laboratory results, median (IQR)
WCC (/109/L) (n=1 124) 9. 2 (7.1 - 11.6) 8 (5.7 - 9.6) 9.5 (7.6 - 12.4) 9.6 (8.5 - 12.4) 0.0001
Hb (g/dL) (n=1 122) 11.3 (9.4 - 13.8) 9.8 (8.5 - 11.7) 12.1 (9.6 - 14.1) 12.7 (9.8 - 14.4) 0.0001
Sodium (mmol/L) (n=1 102) 138 (135 - 141) 135 (132 - 139) 139 (135 - 141) 140 (138 - 143) 0.0001
Urea (mmol/L) (n=1 101) 7.1 (4.7 - 9.7) 5.9 (4 - 8.9) 7.2 (4.9 - 9.8) 8.5 (6.6 - 9.8) 0.0001
Medication, n (%)
Absolute number of medications ≥3 90 (7.6) 48 (15.1) 28 (4) 14 (8.8) <0.0001
5 most common admission medications†
NSAIDs 230 (19.5) 9 (2.8) 138 (19.6) 83 (51.9) <0.0001
Cardiac medications 169 (14.3) 6 (1.9) 109 (15.5) 54 (33.8) <0.0001
Steroids 131 (11.1) 11 (3.5) 101 (14.4) 19 (11.9) <0.0001
TB medications 99 (8.4) 62 (19.5) 36 (5.1) 1 (0.6) <0.0001
Antibiotics 62 (5.3) 49 (15.4) 13 (1.9) 0 <0.0001
Mortality, n (%)
Inpatient 72 (6.2) 22 (7.0) 40 (5.8) 10 (6.3) 0.7540
12 months 281 (23.8) 79 (24.8) 167 (23.7) 35 (21.9) 0.7710
IQR = interquartile range; NCDs = non-communicable diseases; CVS = cardiovascular system; CDs = communicable diseases; TB = tuberculosis; UTI = urinary tract infection;  
WCC = white cell count; Hb = haemoglobin; NSAIDs = non-steroidal anti-inflammatory drugs.
*See Appendix 1 (http://samj.org.za/public/sup/15628.pdf) for detailed diagnoses.
†See Appendix 2 (http://samj.org.za/public/sup/15628.pdf) for details of medications.
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and NCD burdens,[5] and in the setting of improved access to ART. 
The key findings of our study are: (i) delirium occurred in 14.6% 
of all acute medical hospital admissions and 17.6% of HIV-infected 
patients (with 44% ART coverage); (ii) delirium was an independent 
risk factor for inpatient mortality among HIV-infected admissions; 
(iii) ART use at admission was protective against prevalent delirium; 
and (iv) age ≥55 years and urea >15 mmol/L were associated with an 
increased risk of delirium among HIV-infected admissions, rather 
than markers of advanced immunosuppression (low CD4 cell count), 
poor viral control (VL) or active TB. These findings should inform 
clinical practice for generalists and HIV clinicians in developing 
country settings by allowing them to rapidly identify HIV-infected 
patients at risk for prevalent delirium.
Delirium prevalence rates vary widely between studies and are 
dependent on the delirium screening tool used, the study population 
and patient demographics, the burden of disease, and whether the 
study took place in a developing or developed world setting. No 
data are available on HIV-infected medical inpatients in the ART 
era. Our cohort delirium prevalence of 17.6% in HIV-infected 
patients is consistent with both the 4 - 30% published in a recent 





Age (years), median (IQR) 34 (30 - 43.1) 34.6 (29.4 - 41.7) 0.373
Female, n (%) 33 (58.9) 164 (62.6) 0.608
Education ≥7 years, n (%) 28 (73.7) 202 (79.8) 0.385
Primary diagnosis (N=337),* n (%)
Non-communicable total 23 (41.2) 118 (45.0) 0.588
4 most common NCDs
CVS combined 2 (3.6) 27 (10.3)** 0.131
Respiratory 0 11 (4.2) 0.223
Renal failure 5 (8.9) 4 (1.5) 0.010
Liver failure 0 5 (1.9) 0.591
Communicable total 28 (50.0) 114 (43.5) 0.375
2 most common CDs
TB total 18 (32.1) 74 (28.2) 0.559
Pulmonary TB 5 (8.9) 30 (11.5) 0.814
TB meningitis 4 (7.1) 11 (4.2) 0.312
Disseminated TB 7 (12.5) 21 (8) 0.299
Pneumonia 7 (12.5) 20 (7.6) 0.287
HIV-specific diagnoses,‡ n (%) 10 (17.9) 44 (16.8) 0.847
2 most common§
CCM 3 (5.4) 8 (3.1) 0.417
HAND 4 (7.14) 6 (2.29) 0.079
Laboratory results, median (IQR)
CD4 (cells/µL) (n=302) 104 (32 - 214) 150 (62 - 266) 0.1284
Viral suppression (%)¶ (n=86) 3 (27.3) 30 (40) 0.519
WCC (/109/L) (n=309) 8.3 (5.9 - 9.7) 8 (5.7 - 9.5) 0.6299
Hb (g/dL) (n=308) 9.5 (8.1 - 10.3) 9.8 (8.7 - 12.1) 0.0194
Sodium (mmol/L) (n=297) 134.5 (131 - 140) 135 (132 - 139) 0.3279
Urea (mmol/L) (n=297) 7.2 (4.5 - 16.7) 5.7 (3.9 - 8.5) 0.0047
Creatinine (µmol/L) (n=306) 83 (65 - 208) 76 (58 - 94) 0.0197
CRP (mg/L) (n=185) 76.2 (28.9 - 135.2) 45.7 (20 - 107.1) 0.3522
Admission medication,‖ n (%)
Absolute number of medications ≥3 3 (5.4) 45 (17.2) 0.023
ARVs 14 (25.0) 126 (48.1) 0.002
Trimethoprim/sulfamethoxazole 3 (5.4) 38 (14.5) 0.078
TB medications 11 (19.6) 51 (19.5) 0.976
Antibiotics 4 (7.1) 45 (17.2) 0.067
Mortality, n (%)
Inpatient 8 (14.6) 14 (5.4) 0.036
12 months 19 (33.9) 60 (22.9) 0.083
IQR = interquartile range; NCDs = non-communicable diseases; CVS = cardiovascular system; CDs = communicable diseases; TB = tuberculosis; CCM = cryptococcal meningitis;  
HAND = HIV-associated neurocognitive disease; WCC = white cell count; Hb = haemoglobin; CRP = C-reactive protein; ARVs = antiretrovirals.
*See Appendix 1 (http://samj.org.za/public/sup/15628.pdf) for detailed diagnoses.
†19 patients had dual primary diagnoses, i.e. CCM and pulmonary TB. 
‡See Appendix 3 (http://samj.org.za/public/sup/15628.pdf) for details of HIV-specific diagnoses.
§All other diagnoses <3%.
¶Lower than detectable limit or <20 RNA copies/million.
‖See Appendix 2 (http://samj.org.za/public/sup/15628.pdf) for details of medication.
**The diagnoses in this group were venous thromboembolic disease (29.6%), cardiac failure (29.6%), cardiomyopathy (11.1%) and pericarditis (11.3%).
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review on delirium in SSA[6] and the 12 - 57% in US studies[12-15,19] in 
HIV-infected medical inpatients in the pre-ART era. The delirium 
rate was high despite ART coverage of 44% in our cohort. Studies 
show that in general medical wards delirium goes undiagnosed in 
32 - 67% of patients and that this group of patients has an increased 
mortality rate.[20] Lalonde[11] found that only one of 46 HIV-infected 
patients was correctly diagnosed with delirium in a specialist HIV 
centre. These figures together should continue to highlight that even 
as ART coverage continues to improve, delirium surveillance in 
developing countries is an important health priority. In the UK, the 
National Institute for Health and Care Excellence (NICE) recommends 
risk factor and indicator assessment for all patients admitted to 
hospital,[21] and incident delirium is used as a marker of good clinical 
governance. [22]
We found that delirium was associated with increased inpatient 
mortality in HIV-infected patients as well as an (albeit non-significant) 
increase in 12-month mortality. This finding is in keeping with 
previous studies in older patients showing that delirium is related 
to significantly increased short- and long-term mortality. [23,24] The 
mortality rates of our HIV-infected patients with delirium (33.9% at 
12 months and 14.6% as inpatients) were far lower than the inpatient 
mortality rates reported by Uldall and colleagues[9.19] in two studies on 
HIV-infected patients (63% and 97%, respectively), probably because 
our study was done in the era of universal access to ART. However, 
a significantly lower percentage of our HIV-infected patients with 
delirium were on ARVs at the time of admission compared with 
their non-delirious counterparts (25.0% and 48.1%, respectively). 
The protective effect of ART on delirium risk is not surprising, given 
its known benefit in terms of the NCI associated with HIV.[25] These 
findings highlight the need to improve universal access to ART.
We found that older HIV-infected patients with acute renal 
dysfunction were at high risk for inpatient delirium, while those 
using ART on admission seemed to be protected. Similarly, on 
univariable analysis we found three known delirium risk factors to 
be important in our HIV-infected patients: older age, anaemia and 
uraemia. These findings are in keeping with data from Tanzanian 
and Indian general medical inpatient cohorts.[7,26] Anaemia and 
uraemia are well-described risk factors for delirium, and anaemia is 
also a predictor of mortality in HIV-infected patients.[2,27] Uraemia 
probably causes delirium as a result of uraemic encephalopathy, a 
poorly understood process that is thought to involve oxidative stress, 
hormonal and neurotransmitter imbalances, and the accumulation 
of toxic metabolites.[28] However, in our cohort many typical risk 
factors (acute non-OIs, TB and hyponatraemia) were not predictors 
of delirium. We also found that markers of advanced HIV (low CD4 
count and unsuppressed VL) were not significant risk factors for 
delirium, in keeping with the one previous study that assessed CD4 
count.[9]
Interestingly, in our study we found that the more admission 
medications prescribed, the lower the risk of delirium. This high 
number of medications is probably attributable to the pill burden of 
combined ART and the requirement for OI antibiotic prophylaxis 
in HIV-infected patients. This finding is in clear contrast to the 
frequently reported link between polypharmacy and delirium in 
elderly populations;[2] however, this increased risk was also reported 
in HIV-infected cohorts in which the use of three or more CNS active 
medications and medication side-effects were found to be key risk 
factors for delirium.[9,11] Medications that significantly contributed to 
delirium in another study were benzodiazepines and narcotics;[19] this 
was also not found in our study. Notably, all the above studies were 
in the pre-combination ART era[29] and ART use was not reported.
Study limitations
The present study is to our knowledge the largest to date to conduct 
formalised delirium assessments in HIV-infected acute medical 
admissions. Nevertheless, despite the large overall study size, there 
were only 56 cases of delirium in the HIV-infected group. We 
therefore had limited power to detect small differences between 
groups, and the regression analysis findings should be interpreted 
with caution. Our findings will need validation in other developing 
HIV-endemic country settings. Another limitation was the lack of 
mandatory HIV testing on admission, leading to concern about 
possible inclusion bias. Fortunately, only 13.5% of patients were not 
tested for HIV in a large cohort, and there were few missing CD4 
cell count data (but insufficient VL measurements). The HIV not-
tested cohort was a group of older patients with more NCDs, fewer 
infections and less TB, and thought likely to be at low risk of HIV 
infection by the attending clinicians. Although assessing prevalent 
delirium on admission may be difficult owing to incomplete available 
information as well as the fluctuating nature of the condition, a 
further period of observation would only be expected to increase this 
prevalence.
Conclusions
Delirium is highly prevalent and poorly recognised, and has high 
morbidity and mortality that carry a significant cost to healthcare 
systems.[3] We have shown that even with improved ART coverage 
in a developing country setting with a dual burden of HIV and TB, 
Table 3. Univariable and multivariable analysis of risk factors for delirium in HIV-infected patients
Variable Univariable, OR (95% CI)* p-value Multivariable, aOR (95% CI) p-value
Age (per 5-year increase) 1.12 (0.99 - 1.3) 0.065
Age ≥55 years 4.1 (1.6 - 11.1) <0.0001 6.95 (2.03 - 23.67) 0.002
Education ≥7 years 0.71 (0.3 - 1.6) 0.386 0.76 (0.3 - 1.95) 0.583
Laboratory values
CD4 0.99 (0.99 - 1) 0.241 0.84 (0.79 - 1.05) 0.22
Hb 0.9 (0.8 - 0.98) 0.025 0.91 (0.79 - 1.05) 0.22
Urea 1 (1 - 1.1) 0.008
Urea ≥15 mmol/L 5.0 (2.3 - 10.7) <0.0001 4.83 (1.7 - 13.44) 0.003
Medication
ARVs 0.4 (0.2 - 0.7) 0.002 0.34 (0.14 - 0.8) 0.014
OR = odds ratio; CI = confidence interval; aOR = adjusted OR; Hb = haemoglobin; ARVs = antiretrovirals.
*See Appendix 4 (http://samj.org.za/public/sup/15628.pdf) for detailed univariable analysis.
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delirium is common and is associated with inpatient mortality in 
HIV-infected patients. Clinicians need to be aware that ageing HIV-
infected patients who are not on ART and who have renal failure are 
at risk for delirium. In addition, a low CD4 count and elevated VL 
do not increase the likelihood of delirium. Further delirium research 
using a standardised testing method is required to validate these 
findings in other developing countries.
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